You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | CRO概念大升,維亞生物升超9%,藥明康得升超7%

uSMART友信智投7月23日消息,週四港股,CRO概念大升,截至14:36分,維亞生物升8.4%、藥明康得H股升7.17%、康龍化成H股升6.04%、方達控股升5.65%、金斯瑞生物科技升4.68%、藥明生物升0.66%。

港股CRO概念"牛氣衝衝"

泰格醫藥即將加入

港股市場向來對CRO、CMO企業有著天然的好感,6只概念股的股價長期表現優秀,上市至今(2020年7月23日14:30分),藥明生物升超512%藥明康得H股升超260%,維亞生物升超115%,方達控股升超32%,康龍化成H股升超110%金斯瑞生物科技升超1150%

值得注意的是,藥明康得和康龍化成都是"A+H"兩地上市的CRO企業,泰格醫藥將是第三家。市場消息稱,泰格醫藥本次計劃集資10億-15億美元(78億-115億港元),或將成為今年年內亞洲規模最大的醫療IPO,預計於728日開始招股

延伸閱讀:

CRO(醫藥研發合同外包服務機構)

CRO20世紀80年代初起源於美國,它是通過合同形式為製藥企業、醫療機構、中小醫藥醫療器械研發企業、甚至各種政府基金等機構在基礎醫學和臨床醫學研發過程中提供專業化服務的一種學術性或商業性的科學機構。

按照工作的性質,CRO大致分為臨床前研究(Pre-Clinical)CRO和臨床研究CRO。臨床研究CRO以接受委託臨床試驗(Clinical Trial)為主。

 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account